Catalent Inc
NYSE:CTLT
Catalent Inc
Cash from Operating Activities
Catalent Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Catalent Inc
NYSE:CTLT
|
Cash from Operating Activities
$174m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
1%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Catalent Inc's Cash from Operating Activities?
Cash from Operating Activities
174m
USD
Based on the financial report for Dec 31, 2023, Catalent Inc's Cash from Operating Activities amounts to 174m USD.
What is Catalent Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
1%
Over the last year, the Cash from Operating Activities growth was -47%. The average annual Cash from Operating Activities growth rates for Catalent Inc have been -30% over the past three years , -9% over the past five years , and 1% over the past ten years .